Skip to main content

Volume 16 Supplement 3

Sepsis 2012

  • Poster presentation
  • Open access
  • Published:

Polymyxin B-direct hemoperfusion therapy contributes to oxygen delivery in septic patients

Background

Since 1994, Polymyxin B-direct hemoperfusion (PMX-DHP) (Toraymyxin®; Toray Medical Co., Tokyo, Japan) has been approved as a therapy for patients with severe sepsis or septic shock due to Gram-negative infection in Japan. However, its efficacy and indication are still controversial issues. Recently, randomized controlled studies are ongoing in other countries. Our hypothesis is that PMX-DHP therapy may improve the hemodynamic status in septic patients.

Methods

From July 1994 to June 2010, all adult patients treated with PMX-DHP and receiving a pulmonary arterial catheter (PAC) in our ICU were included in this retrospective observational study. Patients' clinical, microbiological and PAC data were collected from medical archives. PAC variables were compared between immediately before and immediately after PMX-DHP therapy. Values were expressed as mean ± SD. Data were analyzed by Wilcoxon signed-ranks test, chi-square test and Fisher's exact probability test. P < 0.05 was considered statistically significant.

Results

Sixty-three patients (36 men, 27 women; age range 24 to 89 years (mean 63.4 ± 14.8)) were studied. The mortality rate was 30.2% at 28 days after PMX-DHP. The APACHE II score and SOFA score on the day of PMX-DHP therapy were 20.2 ± 14.8 and 7.3 ± 3.8, respectively. Mean arterial pressure (MAP; mmHg), cardiac index (CI; l/minute/m2), and oxygen delivery and consumption (DO2 and VO2; ml/minute) significantly improved after PMX-DHP therapy (77.5 ± 22.5 vs. 84.1 ± 23.4, P = 0.0013; 3.9 ± 1.5 vs. 4.3 ± 1.2, P = 0.0006; 951.6 ± 403.5 vs. 1,002.5 ± 394.0, P = 0.013; 233.5 ± 80.6 vs. 248.0 ± 84.1, P = 0.004, respectively). The systemic venous resistance index (SVRI) (dyn second m2/cm5) and mixed venous oxygen saturation (SvO2; %) were not statistically different before and after PMX-DHP therapy (1,573.6 ± 614.6 vs. 1,527.7 ± 575.5, P = 0.069; 71.9 ± 9.0 vs. 74.1 ± 7.5, P = 0.082). The inotropic score and P/F ratio improved after the therapy (9.9 ± 15.9 vs. 7.5 ± 12.5, P = 0.018; 269.8 ± 108.5 vs. 300.6 ± 133.4, P = 0.003).

Conclusion

MAP, CI, DO2, VO2, inotropic score and P/F ratio improved after PMX-DHP therapy, while SVRI and SVO2 did not change. PMX-DHP could contribute to oxygen delivery due to improve hemodynamic status, while decreasing inotropic agents in septic patients.

Author information

Authors and Affiliations

Authors

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Cite this article

Yaguchi, A., Yokota, M., Goto, T. et al. Polymyxin B-direct hemoperfusion therapy contributes to oxygen delivery in septic patients. Crit Care 16 (Suppl 3), P57 (2012). https://doi.org/10.1186/cc11744

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/cc11744

Keywords